SNN (Smith & Nephew) Long-Term Debt: $3,028 Mil (As of Dec. 2025)


SNN Smith & Nephew PLC SNN
86 GF Score
Price $30.70
GF Value $31.61
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Smith & Nephew Long-Term Debt?

Smith & Nephew SNN +0.99% 86 Long-Term Debt is $3,028 Mil as of Dec. 2025. GuruFocus rates SNN with a GF Score™ of 86/100 and a GF Value™ of $31.61 (Fairly Valued). The stock has 3 warning signs investors should review.

Smith & Nephew's Long-Term Debt for the quarter that ended in Dec. 2025 was $3,028 Mil.

Smith & Nephew's quarterly Long-Term Debt increased from Dec. 2024 ($3,123 Mil) to Jun. 2025 ($3,153 Mil) but then declined from Jun. 2025 ($3,153 Mil) to Dec. 2025 ($3,028 Mil).

Smith & Nephew's annual Long-Term Debt increased from Dec. 2023 ($2,175 Mil) to Dec. 2024 ($3,123 Mil) but then declined from Dec. 2024 ($3,123 Mil) to Dec. 2025 ($3,028 Mil).

Smith & Nephew  (NYSE:SNN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Smith & Nephew Long-Term Debt Related Terms

Smith & Nephew Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Smith & Nephew's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Smith & Nephew Long-Term Debt Chart

Smith & Nephew Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,707.00 2,565.00 2,175.00 3,123.00 3,028.00

Smith & Nephew Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,175.00 3,143.00 3,123.00 3,153.00 3,028.00
SNN
86GF Score
Smith & Nephew PLC SNN
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $3,028 Mil mean?
Smith & Nephew (SNN) has a Long-Term Debt of $3,028 Mil as of Dec. 2025.
Is Smith & Nephew's Long-Term Debt too high?
Smith & Nephew's current Long-Term Debt is $3,028 Mil. Overall, Smith & Nephew has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Smith & Nephew's Long-Term Debt compare to ABT and SYK?
Smith & Nephew's Long-Term Debt of $3,028 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Smith & Nephew's current Long-Term Debt is $3,028 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Smith & Nephew stock overvalued right now?
Based on GuruFocus' analysis, Smith & Nephew (SNN) is currently considered Fairly Valued. The stock's GF Value™ is $31.61, compared to a current price of $30.70 — trading 2.9% below its estimated fair value. The current Long-Term Debt is $3,028 Mil. Smith & Nephew's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Smith & Nephew (SNN), the current Long-Term Debt is $3,028 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Smith & Nephew (SNN) Overvalued in 2026?

Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued. The current stock price of $30.70 is trading 2.9% below its estimated GF Value™ of $31.61. GuruFocus considers Smith & Nephew to be Fairly Valued.

Key valuation signals for SNN:

  • Long-Term Debt: $3,028 Mil
  • GF Value™: $31.61 vs. price of $30.70 (2.9% below fair value)
  • GF Score™: 86/100 with 3 warning signs

No single metric tells the full story. See the SNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Smith & Nephew Business Description

Address Hatters Lane, Building 5, Croxley Park, Watford, Hertfordshire, GBR, WD18 8YE
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
86GF Score

Get the complete analysis for SNN

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.70
Price
$31.61
GF Value